TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell’s base demineralized fiber technology, now includes a full portfolio of novel TheraFuze DBF® graft forms, including the DBF Fiber Anchor™ for immediate enhanced screw fixation, DBF Fiber Bullets™ for delivery through a cannula in MIS cases, DBF Fiber Wrap™ and the DBF Fiber Bag™ for graft containment, and a 3-level DBF Fiber Boat™.
TheraCell’s Chief Technology Officer, Andy Carter, Ph.D., said, “These unique DBF allografts, particularly the TheraFuze DBF Fiber Anchor, have been received with great enthusiasm by surgeons in the U.S., and we are excited to make them available to our partner, Australian Biotechnologies.”
TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell's base demineralized fiber technology, now includes a full portfolio of novel...
TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell’s base demineralized fiber technology, now includes a full portfolio of novel TheraFuze DBF® graft forms, including the DBF Fiber Anchor™ for immediate enhanced screw fixation, DBF Fiber Bullets™ for delivery through a cannula in MIS cases, DBF Fiber Wrap™ and the DBF Fiber Bag™ for graft containment, and a 3-level DBF Fiber Boat™.
TheraCell’s Chief Technology Officer, Andy Carter, Ph.D., said, “These unique DBF allografts, particularly the TheraFuze DBF Fiber Anchor, have been received with great enthusiasm by surgeons in the U.S., and we are excited to make them available to our partner, Australian Biotechnologies.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
